Alaunos Therapeutics, Inc. financial data

Symbol
TCRT on Nasdaq
Industry
Pharmaceutical Preparations
Location
2617 Bissonnet St, Suite 225, Houston, TX
State of incorporation
Delaware
Fiscal year end
December 31
Former names
ZIOPHARM ONCOLOGY INC (to 1/4/2022), EASYWEB INC (to 9/19/2005)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 363 % +72.7%
Debt-to-equity 33.5 % -53.1%
Return On Equity -266 % -120%
Return On Assets -199 % -182%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.6M shares -99.3%
Common Stock, Shares, Outstanding 1.6M shares -99.3%
Entity Public Float 94.8M USD -57.2%
Common Stock, Value, Issued 2K USD -99.2%
Weighted Average Number of Shares Outstanding, Basic 1.6M shares +0.16%
Weighted Average Number of Shares Outstanding, Diluted 1.6M shares +0.16%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 6K USD 0%
Research and Development Expense 4.9M USD -80.6%
General and Administrative Expense 8.61M USD -30.7%
Operating Income (Loss) -19.5M USD +43.3%
Nonoperating Income (Expense) 391K USD
Net Income (Loss) Attributable to Parent -19.1M USD +48.1%
Earnings Per Share, Basic 3.1 USD/shares +87.1%
Earnings Per Share, Diluted 3.1 USD/shares +87.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.46M USD -86.6%
Assets, Current 4.68M USD -75.1%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 4.68M USD -83.2%
Accounts Payable, Current 365K USD -75.3%
Accrued Liabilities, Current 542K USD -83.2%
Liabilities, Current 907K USD -82%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 907K USD -85.6%
Retained Earnings (Accumulated Deficit) -919M USD -2.13%
Stockholders' Equity Attributable to Parent 3.77M USD -82.6%
Liabilities and Equity 4.68M USD -83.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.92M USD +79.6%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 5M shares -99%
Common Stock, Shares, Issued 1.6M shares -99.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.92M USD +87.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.46M USD -86.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 211M USD -10.9%
Deferred Tax Assets, Gross 211M USD -11.1%
Operating Lease, Liability 2.75M USD -47.7%
Depreciation 2K USD -99.7%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 3.24M USD -49.9%
Property, Plant and Equipment, Gross 15K USD -99.9%
Operating Lease, Liability, Current 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 780K USD -31.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 757K USD -31.3%
Operating Lease, Weighted Average Discount Rate, Percent 0 pure -96.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 496K USD -59.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 804K USD -31%
Deferred Tax Assets, Operating Loss Carryforwards 148M USD -13.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 712K USD -40.7%
Operating Lease, Payments 100K USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD -100%
Interest Expense 0 USD -100%